Implications of Medicare Negotiation and Most-Favored-Nation Pricing for Cancer Medicine Costs

Thomas J. Hwang, Ariadna Tibau, Aaron S. Kesselheim, Kerstin Noelle Vokinger

Open source

DOI
10.1001/jamahealthforum.2026.0509
Published
2026-05-01
Container
JAMA Health Forum
Publisher
American Medical Association (AMA)
Open access
unknown

Credibility signals

uncertain Score 64/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

Cite this work

BibTeX

@article{allodium:10.1001/jamahealthforum.2026.0509,
  title = {Implications of Medicare Negotiation and Most-Favored-Nation Pricing for Cancer Medicine Costs},
  author = {Thomas J. Hwang and Ariadna Tibau and Aaron S. Kesselheim and Kerstin Noelle Vokinger},
  year = {2026},
  journal = {JAMA Health Forum},
  doi = {10.1001/jamahealthforum.2026.0509},
  url = {https://doi.org/10.1001/jamahealthforum.2026.0509}
}

RIS

TY  - JOUR
TI  - Implications of Medicare Negotiation and Most-Favored-Nation Pricing for Cancer Medicine Costs
AU  - Thomas J. Hwang
AU  - Ariadna Tibau
AU  - Aaron S. Kesselheim
AU  - Kerstin Noelle Vokinger
PY  - 2026
JO  - JAMA Health Forum
DO  - 10.1001/jamahealthforum.2026.0509
UR  - https://doi.org/10.1001/jamahealthforum.2026.0509
ER  - 

APA

Hwang, T. J., Tibau, A., Kesselheim, A. S., & Vokinger, K. N. (2026). Implications of Medicare Negotiation and Most-Favored-Nation Pricing for Cancer Medicine Costs. JAMA Health Forum. https://doi.org/10.1001/jamahealthforum.2026.0509

Source records